CIK 0001787306 · Large accelerated filer
Arcutis Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARQT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812974255
- Phone
- 805-418-5006
- Business address
- 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE, CA, 91361
- Former names
- Arcutis, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,318,251
- in 11 filings, $2.1M under 10b5-1 plans
Net −$3,318,251. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Welgus Howard G. Director | Sale 10b5-1 | −10,000 | $25.65 | $257K | 49,744 |
| 2026-03-02 | Edwards Larry Todd See Remarks | Sale 10b5-1 | −3,584 | $25.16 | $90K | 175,281 |
| 2026-03-02 | Edwards Larry Todd See Remarks | Sale 10b5-1 | −103 | $25.91 | $3K | 175,178 |
| 2026-03-02 | Watanabe Todd See Remarks | Sale 10b5-1 | −36,281 | $25.16 | $913K | 787,025 |
| 2026-03-02 | Watanabe Todd See Remarks | Sale 10b5-1 | −1,068 | $25.91 | $28K | 785,957 |
| 2026-03-02 | Matsuda Masaru See Remarks | Sale 10b5-1 | −6,553 | $25.16 | $165K | 137,125 |
| 2026-03-02 | Matsuda Masaru See Remarks | Sale 10b5-1 | −193 | $25.91 | $5K | 136,932 |
| 2026-03-02 | Matsuda Masaru See Remarks | Sale 10b5-1 | −1,987 | $25.70 | $51K | 136,932 |
| 2026-03-02 | Vairavan Latha SVP Chief Financial Officer | Sale 10b5-1 | −2,772 | $25.16 | $70K | 87,835 |
| 2026-03-02 | Vairavan Latha SVP Chief Financial Officer | Sale 10b5-1 | −81 | $25.91 | $2K | 87,754 |
| 2026-03-02 | Burnett Patrick See Remarks | Sale 10b5-1 | −6,106 | $25.16 | $154K | 121,295 |
| 2026-03-02 | Burnett Patrick See Remarks | Sale 10b5-1 | −181 | $25.91 | $5K | 121,150 |
| 2026-02-27 | Edwards Larry Todd See Remarks | Grant or award 10b5-1 | +30,000 | 178,865 | ||
| 2026-02-27 | Edwards Larry Todd See Remarks | Grant or award · Stock Option (right to buy) 10b5-1 | +77,000 | 77,000 | ||
| 2026-02-27 | Watanabe Todd See Remarks | Grant or award 10b5-1 | +102,000 | 823,306 | ||
| 2026-02-27 | Watanabe Todd See Remarks | Grant or award · Stock Option (right to buy) 10b5-1 | +266,000 | 266,000 | ||
| 2026-02-27 | Matsuda Masaru See Remarks | Grant or award 10b5-1 | +37,000 | 147,003 | ||
| 2026-02-27 | Matsuda Masaru See Remarks | Sale 10b5-1 | −3,325 | $27.95 | $93K | 143,678 |
| 2026-02-27 | Matsuda Masaru See Remarks | Grant or award · Stock Option (right to buy) 10b5-1 | +97,000 | 97,000 | ||
| 2026-02-27 | Vairavan Latha SVP Chief Financial Officer | Grant or award 10b5-1 | +27,000 | 90,607 |
Page 6 of 13 · 241 trades